1. Home
  2. MAX vs PHAR Comparison

MAX vs PHAR Comparison

Compare MAX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediaAlpha Inc.

MAX

MediaAlpha Inc.

HOLD

Current Price

$12.92

Market Cap

722.8M

Sector

Industrials

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$16.46

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAX
PHAR
Founded
2014
1988
Country
United States
Netherlands
Employees
144
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
1.1B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
MAX
PHAR
Price
$12.92
$16.46
Analyst Decision
Buy
Strong Buy
Analyst Count
6
3
Target Price
$17.00
$30.00
AVG Volume (30 Days)
481.1K
23.9K
Earning Date
10-29-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.00
Revenue
$1,123,093,000.00
$362,274,000.00
Revenue This Year
$30.80
$24.80
Revenue Next Year
$9.28
$6.84
P/E Ratio
N/A
$2,952.77
Revenue Growth
64.86
26.78
52 Week Low
$7.33
$7.50
52 Week High
$13.92
$18.12

Technical Indicators

Market Signals
Indicator
MAX
PHAR
Relative Strength Index (RSI) 52.54 49.78
Support Level $12.60 $16.23
Resistance Level $13.46 $17.00
Average True Range (ATR) 0.53 0.78
MACD -0.06 -0.15
Stochastic Oscillator 35.48 29.66

Price Performance

Historical Comparison
MAX
PHAR

About MAX MediaAlpha Inc.

MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: